VEDA VARADA: Open Payments
NPI 1043979420 · RICHLAND, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,712 in 63 payments from 10 companies in 2025. Trend: 2023 $1,086 · 2024 $1,654 · 2025 $1,712
Food & beverage: $1,712
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $384 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $382 |
| Axsome Therapeutics, Inc. | 6 | $308 |
| Otsuka America Pharmaceutical, Inc. | 14 | $255 |
| Alkermes, Inc. | 5 | $128 |
| Supernus Pharmaceuticals, Inc. | 3 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| E.R. Squibb & Sons, L.L.C. | 1 | $38 |
| Lundbeck LLC | 1 | $24 |
Products named: INGREZZA, CAPLYTA, Auvelity, REXULTI, ARISTADA, Qelbree, TRINTELLIX, FANAPT.
Industry payments across WA — which companies pay providers there.
